
    
      This is a double-blind, randomized, parallel, placebo-controlled pilot study on ischemic
      stroke of undetermined source which will be conducted in Bu Ali Sina hospital in Sari, Iran.

      Patients with recent stroke with criteria of ESUS, will be randomized to Rivaroxaban 2.5 mg
      BID plus ASA 80 mg daily or ASA 80 mg plus placebo (1:1 ratio) and have visit every 3 month
      until 1 year
    
  